Copy
CANCER CLINICAL TRIALS NEWSLETTER

This is a prospective, open label, multi-center study of CPI-613® (devimistat) + mFFX compared to FFX in patients with metastatic adenocarcinoma of the pancreas with age range of 18 to 75 years. This study will consist of 2 arms. In the control arm the patients will receive standard of care FFX. The experimental arm will receive Devimstat and modified FFX, which consists of oxaliplatin, folinic acid, irinotecan, and flurouracil via IV infusion. The primary endpoints of this study are Overall response rate and progression free survival. 

(PANC003, IRB 2019-1386)

HCRN-GU17-295
IRB 2019-0593
A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma 
R2810-ONC-1788
IRB 2019-0734
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo After Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma
Click Here to Download All Cancer Trials Open to Accrual
Questions?  Please call us at 513-584-7698, or email us!
New phone-based application available to all UC Cancer Center members and colleagues to aid in patient recruitment into cancer and other research studies.

Have you ever wanted to discuss research participation with a patient, but didn’t have the necessary study information at your fingertips to do so? Now, the UC Cancer Center has partnered with High Enroll, LLC, to provide a valuable tool to solve this problem. This new phone-based application is available for all to use when recruiting patients into studies.

Application users are provided information on each of the Center’s recruiting studies to aid in screening and discussing study participation with patients. This includes study summaries, inclusion and exclusion criteria, other pertinent study information, and a streamlined way to contact the primary research coordinator for each study. IN ORDER TO START USING THIS APPLICATION, go to the website https://ctra.codehatcher.com on your phone and then add the application to your home screen. Your UC Cancer Center research team can also assist you. For further questions please reach out to Dr. Dylan Steen @ 908-208-6927, steendl@ucmail.uc.edu or Ginger Conway @859-992-5339, gingerconway8@gmail.com.
UC researcher studies potential target for cancer

UC researcher has received a grant to study the protein HER3 as a potential biomarker in the treatment and development of breast cancer. 
Click Here to Visit the UC Newsroom
State of the Science Summit: Ovarian Cancer 

Thursday, Sep. 3, 2020  | 5:00pm–9:00pm
Renaissance Cincinnati Downtown Hotel 
36 E. 4th St. Cincinnati, OH 45202

Keynote Speaker:
Thomas Herzog, MD
University of Cincinnati Cancer Center

Ritu Salani, MD
UCLA


For more information or questions, email kelly.hummel@uc.edu, or call 513-558-2030.

View Flyer as PDF
Division of Hematology Oncology Grand Rounds Schedule
Facebook
Twitter
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
CANCER CLINICAL TRIALS NEWSLETTER
Questions?  Please call us at 513-584-7698, or email us!
Facebook
Twitter
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
natalie.ciulla@uc.edu
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
natalie.ciulla@uc.edu
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
natalie.ciulla@uc.edu






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UCCI Clinical Trials · 200 Albert Sabin Way Ste 4002A · Ml 0502 · Cincinnati, OH 45267-0502 · USA